CANF — Can Fite Biopharma Cashflow Statement
0.000.00%
Last trade - 00:00
- $11.13m
- $7.74m
- $0.81m
C2018 December 31st | C2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 20-F | 20-F | 20-F | 20-F | 20-F |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -6.57 | -12.6 | -14.4 | -12.6 | -10.2 |
Depreciation | |||||
Non-Cash Items | 1.27 | 0.571 | 1.93 | 0.313 | 0.659 |
Unusual Items | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | 1.13 | 0.956 | 0.443 | 2.43 | -1.3 |
Change in Accounts Receivable | |||||
Change in Prepaid Expenses | |||||
Change in Accounts Payable | |||||
Change in Accrued Expenses | |||||
Change in Other Liabilities | |||||
Cash from Operating Activities | -4.16 | -11.1 | -12.1 | -9.86 | -10.8 |
Capital Expenditures | -0.033 | -0.003 | -0.026 | -0.011 | -0.009 |
Purchase of Fixed Assets | |||||
Other Investing Cash Flow Items | — | — | — | -14.5 | 9.51 |
Sale/Maturity of Investment | |||||
Purchase of Investments | |||||
Cash from Investing Activities | -0.033 | -0.003 | -0.026 | -14.5 | 9.5 |
Net Issuance / Retirement of Stock | |||||
Cash from Financing Activities | 4.39 | 10.2 | 17.7 | 20.5 | 0 |
Foreign Exchange Effects | |||||
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | 0.11 | -0.918 | 5.57 | -3.88 | -1.41 |